|
ATG/ALG
|
Binds multiple antigens on lymphoid cells
|
Complement-mediated lysis
|
Serum sickness
|
Batch variability
|
| | |
Opsonization and clearance
|
Thrombocytopenia
| |
| | |
Modification of cell surface receptor
|
Granulocytopenia
| |
|
OKT3
|
Binds T cell CD3
|
Complement mediated lysis
|
Cytokine release syndrome
|
Tachyphylaxis due to anti-idiotypic antibodies
|
| | |
Opsonization and clearance
|
(eg fever, chills, headache, and pulmonary edema)
| |
| | |
Modification of CD3 receptor
| | |
|
Daclizumab
|
Binds α-subunit of interleukin-2 receptor
|
Down-regulation of receptor
|
No major side effects reported so far
|
Humanized antibody
|
| | |
? CD4 T cell depletion
| |
Long half-life (20 days)
|
| | | | |
Five-dose regimen
|
|
Basiliximab
|
Binds α-subunit of interleukin-2 receptor
|
Down-regulation of receptor
|
No major side effects reported so far
|
Chimeric antibody
|
| | |
? CD4 T cell depletion
| |
Long half-life (10-14 days)
|
| | | | |
Two-dose regimen
|
